MX2015000683A - Metodo para producir moleculas monomericas y multimericas y uso de las mismas. - Google Patents
Metodo para producir moleculas monomericas y multimericas y uso de las mismas.Info
- Publication number
- MX2015000683A MX2015000683A MX2015000683A MX2015000683A MX2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A MX 2015000683 A MX2015000683 A MX 2015000683A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- denotes
- mer
- region
- biologically active
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 230000004927 fusion Effects 0.000 abstract 3
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
Abstract
Aquí se reporta un método para la producción de un polipéptido que es activo biológicamente como n-mer que comprende un ácido nucléico que codifica un polipéptido de fusión de acuerdo con la siguiente fórmula (Bn-CS0-Is-CSp-FC-CSq-It-CSr-Bm)u, en donde B denota un polipéptido que es biológicamente activo como n-mer y forma agregados/multímeros no definidos durante la expresión en la ausencia de una región de Fc fusionada, FC denota un polipéptido de la región de Fc de cadena pesada, CS denota un sitio de escisión, e I denota una secuencia de aminoácidos de intervención, en donde FC no se aglutina substancialmente a un receptor de Fc, recuperar el polipéptido de fusión de la célula o del medio de cultivo, escindiendo opcionalmente el polipéptido de fusión con una proteasa, y producir por esto un polipéptido que es biológicamente activo como n-mer y forma agregados/multímeros no definidos durante la expresión en la ausencia de una región de Fc fusionada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179021 | 2012-08-02 | ||
| PCT/EP2013/066096 WO2014020069A1 (en) | 2012-08-02 | 2013-07-31 | Method for producing monomeric and multimeric molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015000683A true MX2015000683A (es) | 2015-04-10 |
Family
ID=48914281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000683A MX2015000683A (es) | 2012-08-02 | 2013-07-31 | Metodo para producir moleculas monomericas y multimericas y uso de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150218250A1 (es) |
| EP (1) | EP2880169B1 (es) |
| JP (1) | JP6388581B2 (es) |
| KR (1) | KR20150037959A (es) |
| CN (1) | CN104508133B (es) |
| BR (1) | BR112015002091A2 (es) |
| CA (1) | CA2876099A1 (es) |
| ES (1) | ES2633894T3 (es) |
| MX (1) | MX2015000683A (es) |
| RU (1) | RU2015106812A (es) |
| SG (1) | SG11201408530YA (es) |
| WO (1) | WO2014020069A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016020368A2 (pt) | 2014-03-05 | 2018-01-23 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| CA2954754C (en) * | 2014-07-15 | 2023-01-17 | Astellas Pharma Inc. | Novel anti-human tie-2 antibody |
| BR112017006591A2 (pt) * | 2014-11-06 | 2018-01-16 | Hoffmann La Roche | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2018025809A1 (ja) * | 2016-08-01 | 2018-02-08 | 株式会社カネカ | カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法 |
| DK3511340T3 (da) | 2016-08-10 | 2025-01-02 | Univ Ajou Ind Academic Coop Found | Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| IL303806B2 (en) * | 2016-12-22 | 2024-05-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
| KR101955928B1 (ko) | 2016-12-30 | 2019-03-08 | 경상대학교산학협력단 | 먹장어 유래 vlrb 단백질의 소수성 테일 도메인을 포함하는 다량체 다가 중합체 |
| CN111315395A (zh) | 2017-09-06 | 2020-06-19 | 耶鲁大学 | 白细胞介素-18变体和使用方法 |
| ES2873650T3 (es) * | 2017-09-19 | 2021-11-03 | Tillotts Pharma Ag | Variantes de anticuerpos |
| US11987609B2 (en) | 2017-09-25 | 2024-05-21 | Dingfu Biotarget Co., Ltd. | Proteinaceous heterodimer and use thereof |
| KR20250024101A (ko) | 2018-04-25 | 2025-02-18 | 프로메테우스 바이오사이언시즈, 인크. | 최적화된 항tl1a 항체 |
| JP7676150B2 (ja) * | 2018-06-01 | 2025-05-14 | サノフイ | Ｂ型肝炎ウイルス感染を治療するための併用療法 |
| TWI891611B (zh) | 2018-10-23 | 2025-08-01 | 美商蜻蜓醫療公司 | 異二聚體fc融合蛋白 |
| WO2020257191A1 (en) * | 2019-06-19 | 2020-12-24 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL292419A (en) | 2019-10-24 | 2022-06-01 | Prometheus Biosciences Inc | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| EP4199953A4 (en) | 2020-08-19 | 2024-11-06 | Janssen Biotech, Inc. | MATERIALS AND METHODS OF USING MODIFIED LIGANDS |
| CA3197642A1 (en) * | 2020-10-09 | 2022-04-14 | The Hospital For Sick Children | Polypeptides targeting sars-cov-2 and related compositions and methods |
| TW202241932A (zh) * | 2020-12-23 | 2022-11-01 | 美商默沙東藥廠 | 用於治療自體免疫及發炎性疾病之il-2突變蛋白 |
| CN118580372A (zh) * | 2023-03-01 | 2024-09-03 | 广东菲鹏制药股份有限公司 | 靶向TGFβ的融合蛋白及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4105480A1 (de) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
| US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| WO2000003737A2 (en) | 1998-07-17 | 2000-01-27 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble drugs and methods for their production |
| EP1141013A2 (en) * | 1999-01-07 | 2001-10-10 | Lexigen Pharmaceuticals Corp. | EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4944324B2 (ja) * | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| JP2005505494A (ja) | 2001-02-23 | 2005-02-24 | イミュネックス・コーポレーション | 活性タンパク質の回収増加 |
| WO2003068977A2 (de) * | 2002-02-10 | 2003-08-21 | Apoxis Sa | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
| CA2652570A1 (en) * | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| AT505262A1 (de) | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
| WO2010048313A2 (en) | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
| EP2184070A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| KR20160044598A (ko) * | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2012146630A1 (en) * | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
-
2013
- 2013-07-31 WO PCT/EP2013/066096 patent/WO2014020069A1/en not_active Ceased
- 2013-07-31 KR KR1020157002700A patent/KR20150037959A/ko not_active Withdrawn
- 2013-07-31 MX MX2015000683A patent/MX2015000683A/es unknown
- 2013-07-31 SG SG11201408530YA patent/SG11201408530YA/en unknown
- 2013-07-31 ES ES13744530.0T patent/ES2633894T3/es active Active
- 2013-07-31 CN CN201380040175.9A patent/CN104508133B/zh active Active
- 2013-07-31 JP JP2015524776A patent/JP6388581B2/ja active Active
- 2013-07-31 EP EP13744530.0A patent/EP2880169B1/en active Active
- 2013-07-31 CA CA2876099A patent/CA2876099A1/en not_active Abandoned
- 2013-07-31 RU RU2015106812A patent/RU2015106812A/ru not_active Application Discontinuation
- 2013-07-31 BR BR112015002091A patent/BR112015002091A2/pt not_active IP Right Cessation
-
2015
- 2015-02-02 US US14/611,566 patent/US20150218250A1/en not_active Abandoned
-
2017
- 2017-05-09 US US15/590,374 patent/US10570188B2/en active Active
-
2020
- 2020-01-30 US US16/777,138 patent/US11254728B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104508133A (zh) | 2015-04-08 |
| US10570188B2 (en) | 2020-02-25 |
| JP2015531591A (ja) | 2015-11-05 |
| US20200157183A1 (en) | 2020-05-21 |
| KR20150037959A (ko) | 2015-04-08 |
| US20170342128A1 (en) | 2017-11-30 |
| EP2880169B1 (en) | 2017-05-17 |
| CA2876099A1 (en) | 2014-02-06 |
| US11254728B2 (en) | 2022-02-22 |
| EP2880169A1 (en) | 2015-06-10 |
| JP6388581B2 (ja) | 2018-09-12 |
| RU2015106812A (ru) | 2016-09-27 |
| WO2014020069A1 (en) | 2014-02-06 |
| US20150218250A1 (en) | 2015-08-06 |
| CN104508133B (zh) | 2018-04-20 |
| HK1208880A1 (en) | 2016-03-18 |
| ES2633894T3 (es) | 2017-09-25 |
| SG11201408530YA (en) | 2015-03-30 |
| BR112015002091A2 (pt) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015000683A (es) | Metodo para producir moleculas monomericas y multimericas y uso de las mismas. | |
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| GB201008682D0 (en) | Epitope tag for affinity based applications | |
| PH12013500995A1 (en) | Methods for increasing yield and fine chemical production in plants | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| NZ630848A (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
| MX2015000681A (es) | Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas. | |
| EP3597664A3 (en) | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells | |
| BR112015020111A8 (pt) | célula de levedura recombinante, vetores para a expressão funcional de um polipeptídeo heterólogo, método para preparar um álcool, ácido orgânico ou aminoácido, uso de dióxido de carbono, e, microorganismo recombinante | |
| TN2015000379A1 (en) | BISPECIFIC-Fc MOLECULES | |
| NZ705575A (en) | Recombinant clostridium botulinum neurotoxins | |
| JP2015514423A5 (es) | ||
| PH12015502614A1 (en) | Thrombin cleavable linker with xten and its uses thereof | |
| MY181068A (en) | Recombinant microorganism for improved production of fine chemicals | |
| NZ719881A (en) | Plant cytochrome p450 | |
| NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
| MX368656B (es) | Métodos mejorados para la producción de polipéptidos recombinantes. | |
| HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf | |
| PH12016501094A1 (en) | Recombinant microorganism for improved production of fine chemicals | |
| MX361434B (es) | Proteínas de fusión npp1. | |
| WO2012028523A3 (en) | Prokaryotic expression construct | |
| MY184387A (en) | Improved surface display of functional proteins in a broad range of gram negative bacteria | |
| WO2009066320A3 (en) | Gcsf fusion protein systems suitable for high expression of peptides | |
| EA201400192A1 (ru) | Клетка, ферментирующая пентозы | |
| IN2014DN06660A (es) |